The Developmental Research Program (DRP) is an integral part of the UCSF Brain Tumor SPORE and represents the best opportunity to explore new ideas as pilot projects, to develop new resources, to apply new technologies to translational brain tumor research, and to promote collaborations among scientists at UCSF and outside institutions. In this manner the DRP ultimately serves as a means to build and support new technologies, to support the early stage development of projects that can compete successfully for peer- reviewed funding, and, in the best case scenario, for inclusion as full projects in the SPORE Program.
The Specific Aims of the UCSF Brain Tumor SPORE DRP are: 1. To implement new technologies and resources for translational brain tumor research 2. To help develop collaborations among scientists within UCSF and at different institutions 3. To develop new ideas as pilot projects to replace SPORE projects or generate other funding

Public Health Relevance

The Developmental Research Program is required component of all SPOREs and must be maintained for the entire funding period. Funds provided by the UCSF Brain Tumor SPORE, supplemented by funds provided by the UCSF Department of Neurological Surgery through the Helen Diller Family Comprehensive Cancer Center (HDFCCC), allow the SPORE to provide $50,000 direct costs for up to three DRP projects per year.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097257-18
Application #
9999434
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-20
Project End
2023-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
18
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Takahashi, Hannah; Cornish, Alex J; Sud, Amit et al. (2018) Mendelian randomisation study of the relationship between vitamin D and risk of glioma. Sci Rep 8:2339
Amirian, E Susan; Ostrom, Quinn T; Armstrong, Georgina N et al. (2018) Aspirin, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-Analysis. Cancer Epidemiol Biomarkers Prev :
Griveau, Amelie; Seano, Giorgio; Shelton, Samuel J et al. (2018) A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. Cancer Cell 33:874-889.e7
Disney-Hogg, Linden; Cornish, Alex J; Sud, Amit et al. (2018) Impact of atopy on risk of glioma: a Mendelian randomisation study. BMC Med 16:42
Wang, Qianghu; Hu, Baoli; Hu, Xin et al. (2018) Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell 33:152
Salas, Lucas A; Wiencke, John K; Koestler, Devin C et al. (2018) Tracing human stem cell lineage during development using DNA methylation. Genome Res 28:1285-1295
Ostrom, Quinn T; Kinnersley, Ben; Wrensch, Margaret R et al. (2018) Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. Sci Rep 8:7352
Salas, Lucas A; Koestler, Devin C; Butler, Rondi A et al. (2018) An optimized library for reference-based deconvolution of whole-blood biospecimens assayed using the Illumina HumanMethylationEPIC BeadArray. Genome Biol 19:64
Choi, Serah; Yu, Yao; Grimmer, Matthew R et al. (2018) Temozolomide-associated hypermutation in gliomas. Neuro Oncol 20:1300-1309
Jacobs, Daniel I; Liu, Yanhong; Gabrusiewicz, Konrad et al. (2018) Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. J Neurooncol 136:33-39

Showing the most recent 10 out of 362 publications